ANI Pharmaceuticals (NASDAQ: ANIP) is preparing to announce its third-quarter earnings for 2025 on November 7, 2025, prior to the market opening. Analysts predict the company will report earnings of $1.74 per share, along with estimated revenues of $211.9 million for the quarter. The financial results will be detailed on a conference call scheduled at 8:30 AM ET.
In its previous earnings release on June 8, 2025, ANI Pharmaceuticals reported a loss of ($0.12) per share, with revenues totaling $64.48 million. The company had a negative net margin of 1.37%, yet a positive return on equity of 25.03%. Analysts are forecasting earnings of $4 per share for both the current and next fiscal years.
Stock Performance and Insider Trading Activity
On November 6, 2025, shares of ANI Pharmaceuticals opened at $92.62. The stock has experienced fluctuations over the past year, reaching a low of $52.50 and a high of $99.50. The company has a market capitalization of $2.01 billion and a debt-to-equity ratio of 1.39. Its price-to-earnings (P/E) ratio currently stands at -120.28, with a beta of 0.54.
Recent insider trading activity has raised eyebrows. Senior Vice President Chad Gassert sold 20,000 shares on August 15, 2025, at an average price of $86.97, generating a total of $1,739,400. This transaction represented a 10.35% decrease in Gassert’s holdings, which now total 173,226 shares, valued at approximately $15,065,465.22.
Additionally, Chief Financial Officer Stephen P. Carey sold 50,000 shares on August 12, 2025, at an average price of $86.07, amounting to $4,303,500. Following this sale, Carey holds 180,863 shares worth about $15,566,878.41. In total, insiders have disposed of 413,830 shares valued at $36,505,378 in the last quarter, with corporate insiders now owning 12.70% of the company’s stock.
Institutional Investors’ Influence
Institutional investors and hedge funds have been active in adjusting their stakes in ANI Pharmaceuticals. For instance, Canada Life Assurance Co increased its holdings by 1.0% during the second quarter, now owning 19,408 shares valued at $1,267,000. Similarly, Thrivent Financial for Lutherans enhanced its position by 2.6%, obtaining 12,511 shares worth $816,000.
UBS Asset Management Americas LLC has also raised its stake by 0.9%, acquiring 48,322 shares valued at $3,235,000. New investments have been made by Advisors Asset Management Inc., which initiated a position worth approximately $28,000. Currently, institutional and hedge fund investors hold 76.05% of ANI Pharmaceuticals’ stock.
ANI Pharmaceuticals, Inc. specializes in developing, manufacturing, and marketing both branded and generic prescription pharmaceuticals in the United States and Canada. The company’s portfolio includes oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products, along with contract development and manufacturing services for pharmaceutical products.
